(VIANEWS) – Blackrock MuniHoldings New Jersey Quality Fund (MUJ), American Software (AMSWA), Waterstone Financial (WSBF) have the highest dividend yield stocks on this list.
| Financial Asset | Forward Dividend Yield | Updated (EST) |
|---|---|---|
| Blackrock MuniHoldings New Jersey Quality Fund (MUJ) | 4.94% | 2024-09-14 05:08:05 |
| American Software (AMSWA) | 4.02% | 2024-09-16 15:06:05 |
| Waterstone Financial (WSBF) | 3.83% | 2024-09-22 09:12:05 |
| Federal Realty Investment Trust (FRT) | 3.78% | 2024-09-12 19:14:06 |
| AbbVie (ABBV) | 3.2% | 2024-09-22 03:14:24 |
Almost 2K companies listed in the Nasdaq and NYSE pay out dividends to its shareholders. The dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.
1. Blackrock MuniHoldings New Jersey Quality Fund (MUJ) – Dividend Yield: 4.94%
Blackrock MuniHoldings New Jersey Quality Fund’s last close was $12.14, 0.33% below its 52-week high of $12.18. Intraday change was 0.08%.
BlackRock MuniHoldings New Jersey Quality Fund, Inc. is a close ended fixed income mutual fund launched by BlackRock, Inc. The fund is managed by BlackRock Advisors, LLC. It invests in the fixed income markets of United States. The fund invests primarily in long-term, investment grade municipal obligations exempt from federal income taxes and New Jersey personal income taxes. The fund was formerly known as BlackRock MuniHoldings New Jersey Insured Fund. BlackRock MuniHoldings New Jersey Quality Fund, Inc. was formed in 1998 and is domiciled in United States.
Earnings Per Share
As for profitability, Blackrock MuniHoldings New Jersey Quality Fund has a trailing twelve months EPS of $0.44.
PE Ratio
Blackrock MuniHoldings New Jersey Quality Fund has a trailing twelve months price to earnings ratio of 27.59. Meaning, the purchaser of the share is investing $27.59 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 2.96%.
More news about Blackrock MuniHoldings New Jersey Quality Fund.
2. American Software (AMSWA) – Dividend Yield: 4.02%
American Software’s last close was $10.95, 10.76% below its 52-week high of $12.27. Intraday change was 0.37%.
American Software, Inc. develops, markets, and supports a range of computer business application software products in the United States and internationally. The company operates in three segments: Supply Chain Management (SCM), Information Technology Consulting (IT Consulting), and Other. The SCM segment offers Logility Digital Supply Chain Platform, a cloud-architected supply chain management platform that helps manage seven critical planning processes, such as product, demand, inventory, supply, deploy, integrated business planning, and supply chain data management. The IT Consulting segment provides IT staffing and consulting services, such as software enhancement, documentation, update, customer education, consulting, systems integration, maintenance, and support services. The Other segment offers American Software ERP, which provides purchasing and materials management, customer order processing, financial, e-commerce, and traditional manufacturing solutions. It also provides ongoing support and maintenance services; cloud hosting and managed services; and implementation and training services. The company markets its products through direct and indirect sales channels to the apparel and other soft goods, food and beverage, consumer packaged goods, consumer durable goods, wholesale distribution, specialty chemicals, and other process manufacturing industries. American Software, Inc. was incorporated in 1970 and is headquartered in Atlanta, Georgia.
Earnings Per Share
As for profitability, American Software has a trailing twelve months EPS of $0.27.
PE Ratio
American Software has a trailing twelve months price to earnings ratio of 40.7. Meaning, the purchaser of the share is investing $40.7 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 6.75%.
More news about American Software.
3. Waterstone Financial (WSBF) – Dividend Yield: 3.83%
Waterstone Financial’s last close was $15.67, 4.22% below its 52-week high of $16.36. Intraday change was -3.69%.
Waterstone Financial, Inc. operates as a bank holding company for WaterStone Bank SSB that provides various financial services to customers in southeastern Wisconsin, the United States. It operates in two segments, Community Banking and Mortgage Banking. The Community Banking segment offers consumer and business banking products and services, such as deposit and transactional solutions, including checking accounts, online banking and bill pay services, money transfer services, as well as credit, debit, and pre-paid cards; investable funds solutions comprising savings, money market deposits, individual retirement accounts, and certificates of deposit; residential mortgages, home equity loans and lines of credit, personal and installment loans, real estate financing, business loans, and business lines of credit; and fixed and variable annuities, insurance products, and trust and investment management accounts. It also provides transaction deposits, interest bearing transaction accounts, demand deposits, non-interest-bearing demand accounts, and time deposits; secured and unsecured lines; commercial real estate construction loans; term loans for working capital, inventory, and general corporate use; and personal term loans and investment services. The Mortgage Banking segment offers residential mortgage loans for the purpose of sale in the secondary market. It also invests in a portfolio of securities include mortgage-backed securities, government-sponsored and private-label enterprise bonds, collateralized mortgage and municipal obligations, and other debt securities. The company was formerly known as Wauwatosa Holdings, Inc. and changed its name to Waterstone Financial, Inc. in August 2008. The company was founded in 1921 and is based in Wauwatosa, Wisconsin.
Earnings Per Share
As for profitability, Waterstone Financial has a trailing twelve months EPS of $0.63.
PE Ratio
Waterstone Financial has a trailing twelve months price to earnings ratio of 24.87. Meaning, the purchaser of the share is investing $24.87 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 3.46%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 3.9%, now sitting on 132.56M for the twelve trailing months.
Dividend Yield
As stated by Morningstar, Inc., the next dividend payment is on Jul 8, 2024, the estimated forward annual dividend rate is 0.6 and the estimated forward annual dividend yield is 3.83%.
Sales Growth
Waterstone Financial’s sales growth is negative 19.5% for the current quarter and negative 24.7% for the next.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, Waterstone Financial’s stock is considered to be overbought (>=80).
More news about Waterstone Financial.
4. Federal Realty Investment Trust (FRT) – Dividend Yield: 3.78%
Federal Realty Investment Trust’s last close was $116.26, 1.18% below its 52-week high of $117.65. Intraday change was -0.02%.
Federal Realty is a recognized leader in the ownership, operation and redevelopment of high-quality retail-based properties located primarily in major coastal markets from Washington, D.C. to Boston as well as San Francisco and Los Angeles. Founded in 1962, Federal Realty's mission is to deliver long-term, sustainable growth through investing in communities where retail demand exceeds supply. Its expertise includes creating urban, mixed-use neighborhoods like Santana Row in San Jose, California, Pike & Rose in North Bethesda, Maryland and Assembly Row in Somerville, Massachusetts. These unique and vibrant environments that combine shopping, dining, living and working provide a destination experience valued by their respective communities. Federal Realty's 106 properties include approximately 3,100 tenants, in 25 million square feet, and approximately 3,200 residential units. Federal Realty has increased its quarterly dividends to its shareholders for 54 consecutive years, the longest record in the REIT industry. Federal Realty is an S&P 500 index member and its shares are traded on the NYSE under the symbol FRT. For additional information about Federal Realty and its properties, visit www.federalrealty.com.
Earnings Per Share
As for profitability, Federal Realty Investment Trust has a trailing twelve months EPS of $3.41.
PE Ratio
Federal Realty Investment Trust has a trailing twelve months price to earnings ratio of 34.09. Meaning, the purchaser of the share is investing $34.09 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 9.33%.
Volume
Today’s last reported volume for Federal Realty Investment Trust is 990421 which is 76.15% above its average volume of 562237.
Sales Growth
Federal Realty Investment Trust’s sales growth for the next quarter is 5.6%.
More news about Federal Realty Investment Trust.
5. AbbVie (ABBV) – Dividend Yield: 3.2%
AbbVie’s last close was $193.83, 3.06% under its 52-week high of $199.95. Intraday change was -2.22%.
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; and Genentech, Inc., as well as collaboration with Tentarix Biotherapeutics, LP to develop conditionally-active and multi-specific biologics for oncology and immunology. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Earnings Per Share
As for profitability, AbbVie has a trailing twelve months EPS of $2.71.
PE Ratio
AbbVie has a trailing twelve months price to earnings ratio of 59.88. Meaning, the purchaser of the share is investing $59.88 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 54.26%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 4.3%, now sitting on 55B for the twelve trailing months.
Yearly Top and Bottom Value
AbbVie’s stock is valued at $162.28 at 20:15 EST, way below its 52-week high of $199.95 and way higher than its 52-week low of $135.85.
Sales Growth
AbbVie’s sales growth is 4% for the current quarter and 2.2% for the next.
More news about AbbVie.
